Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72642
Title:
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.
Authors:
Renehan, Andrew G; Harvie, Michelle N; Howell, Anthony ( 0000-0002-3879-5991 )
Abstract:
Insulin-like growth factor (IGF)-I, and its main binding protein, IGFBP-3, are multi-functional regulatory peptides of cell growth and survival, attributes important for tumourigenesis. Following seminal work published in 1998, it has been hypothesised that circulating concentrations of these growth factors may be associated with cancer risk. Systematic reviews have reported that high normal range circulating levels of total IGF-I predict for pre- but not post-menopausal breast cancer. By contrast, associations with circulating IGFBP-3 have been inconsistent. A cumulative meta-analysis demonstrates that earlier reported positive associations between IGFBP-3 and pre-menopausal breast cancer risk now seem less clear as large-size cohorts are published. The reasons are complex and include differences in study design, lack of standardisation between assays, and variations in IGFBP-3 proteolytic activity--these are discussed in this commentary.
Affiliation:
Department of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. arenehan@picr.man.ac.uk
Citation:
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. 2006, 13 (2):273-8 Endocr. Relat. Cancer
Journal:
Endocrine-Related Cancer
Issue Date:
Jun-2006
URI:
http://hdl.handle.net/10541/72642
DOI:
10.1677/erc.1.01219
PubMed ID:
16728563
Type:
Article
Language:
en
ISSN:
1351-0088
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorRenehan, Andrew G-
dc.contributor.authorHarvie, Michelle N-
dc.contributor.authorHowell, Anthony-
dc.date.accessioned2009-07-06T16:07:44Z-
dc.date.available2009-07-06T16:07:44Z-
dc.date.issued2006-06-
dc.identifier.citationInsulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. 2006, 13 (2):273-8 Endocr. Relat. Canceren
dc.identifier.issn1351-0088-
dc.identifier.pmid16728563-
dc.identifier.doi10.1677/erc.1.01219-
dc.identifier.urihttp://hdl.handle.net/10541/72642-
dc.description.abstractInsulin-like growth factor (IGF)-I, and its main binding protein, IGFBP-3, are multi-functional regulatory peptides of cell growth and survival, attributes important for tumourigenesis. Following seminal work published in 1998, it has been hypothesised that circulating concentrations of these growth factors may be associated with cancer risk. Systematic reviews have reported that high normal range circulating levels of total IGF-I predict for pre- but not post-menopausal breast cancer. By contrast, associations with circulating IGFBP-3 have been inconsistent. A cumulative meta-analysis demonstrates that earlier reported positive associations between IGFBP-3 and pre-menopausal breast cancer risk now seem less clear as large-size cohorts are published. The reasons are complex and include differences in study design, lack of standardisation between assays, and variations in IGFBP-3 proteolytic activity--these are discussed in this commentary.en
dc.language.isoenen
dc.subject.meshBreast Neoplasms-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor Binding Protein 3-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshRisk Factors-
dc.titleInsulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. arenehan@picr.man.ac.uken
dc.identifier.journalEndocrine-Related Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.